A study to assess the immunogenicity and safety of GSK Biologicals’ Infanrix-IPV/Hib vaccine administered as a three-dose vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age in healthy infants in Russia

Trial Identifier: 116194
Sponsor: GlaxoSmithKline
Start Date: September 2016
Primary Completion Date: October 2017
Condition: Hepatitis B

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Russian Federation Barnaul, Russian Federation, 656056
Russian Federation Ekaterinburg, Russian Federation, 620131
Russian Federation Murmansk, Russian Federation, 183038
Russian Federation St.Petersburg, Russian Federation, 191025
Russian Federation Tomsk, Russian Federation, 634 050